Lupin gets 3 observations from USFDA for its Tarapur facility
The inspection of Tarapur facility was carried out by the United States Food and Drug administration (USFDA) between September…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Lupin
Lupin appoints Jon Stelzmiller as President of US Specialty Business
He brings to Lupin over 30 years of experience in the specialty segment, and will be replacing Nicholas Hart
Lupin gets warning letter from US FDA for Mandideep facility
Lupin said there are no drug master file and abbreviated new drug applications (ANDA) pending review or approval from the…
Lupin receives US FDA approval for Fosaprepitant Injection
The drug is indicated for the prevention of acute and delayed nausea and vomiting
Lupin has received approval for its…
Lupin and Boehringer Ingelheim partner to develop and commercialise novel oncology drug to treat…
The partnership aims to develop Lupin’s lead MEK inhibitor compound in combination with one of Boehringer Ingelheim’s innovative…
Lupin’s South African arm Pharma Dynamics signs commercial agreement with Creso Pharma
The agreement gives Pharma Dynamics distribution rights hemp oil-based cannaQIX products across South Africa, Namibia, Botswana,…
Lupin to sell Japanese Injectables business to Neopharma Group
The transaction is subject to customary closing conditions, has been approved by BoD of Lupin
Lupin Q1 net profit up 49 pc to Rs 303.05
The company had posted a net profit of Rs 202.76 crore in the year-ago period
Lupin’s Mandideep facility inspection completed by ANSM
The inspection closed with no critical or major observations
Lupin gets EIR from USFDA for Aurangabad facility
The facility was inspected by the US Food and Drug Administration (US FDA) between May 6-15, 2019, Lupin said in a BSE filing